New insights into the autoantibody-mediated mechanisms of autoimmune bullous diseases and urticaria

Clinical and Experimental Rheumatology

Volumn 24, Issue SUPPL. 40, 2006, Pages

  Blank, M ^a,c   Gisondi, P ^b   Mimouni, D ^c   Peserico, A ^d   Piaserico, S ^d   Shoenfeld, Y ^a,c   Reunala, R ^e   Zambruno, G ^f   Di Zenzo, G ^f   Girolomoni, Giampiero ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF VERONA   (Italy)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF PADOVA   (Italy)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Autoantibodies; Autoimmune bullous diseases; Bullous pemphigoid; Dermatitis herpetiformis; Pathophysiology; Pemphigus vulgaris; Urticaria

Indexed keywords

ALPHA6 INTEGRIN; AMPHETAMINE DERIVATIVE; ATROPINE; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CEPHALOSPORIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESMOGLEIN 3 ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIADIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDRALAZINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; INSULIN; KALININ; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACANTHOLYSIS; AUTOIMMUNE SKIN DISEASE; BULLOUS SKIN DISEASE; CELIAC DISEASE; CELL ADHESION; DERMATITIS HERPETIFORMIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EPIDERMIS CELL; EPITHELIUM CELL; FOOD ALLERGY; GLUTEN FREE DIET; HEMIDESMOSOME; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAST CELL DEGRANULATION; MORTALITY; NONHUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; PEMPHIGOID; PEMPHIGUS VULGARIS; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; TREATMENT RESPONSE; URTICARIA; WHEAT;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; DERMATITIS HERPETIFORMIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PEMPHIGOID, BULLOUS; PEMPHIGUS; SKIN; SKIN DISEASES, VESICULOBULLOUS; URTICARIA;

EID: 33645030473     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. LIU Z, DIAZ LA: Bullous pemphigoid: end of the century overview. J Dermatol 2001; 28: 647-50.
2. CHAN LS, AHMED AR, ANHALT JB et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-9.
3. GIUDICE GJ, EMERY DJ, ZELICKSON BD, ANHALT GJ, LIU Z, DIAZ LA: Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 5742-50.
4. DI ZENZO G, GROSSO F, TERRACINA M et al.: Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004; 122: 103-10.
5. 2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119: 1065-73.
6. LIU Z, DIAZ LA, TROY JL et al.: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480-88.
7. LIU Z, ZHOU X, SHAPIRO SD et al.: The serpin alpha1-protemase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000; 102: 647-55.
8. KISS M, HUSZ S, JANOSSY T et al.: Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005; 24: 1-10.
9. LAZAROVA Z, YEE C, DARLING T, BRIGGAMAN RA, YANCEY KB: Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996; 98: 1509-18.
10. BHOL KC, COLON JE, AHMED AR: Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J Invest Dermatol 2003; 120: 701-2.
11. STANLEY JR: Pemphigus. In: FREEDBERG IM, EISEN AZ, WOLFF K et al. (Eds.): Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill; 1999:654-666.
12. ANHALT GJ, LABIB RS, VOORHEES JJ, BEALS TF, DIAZ LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-96.
13. AMAGAI M, HASHIMOTO T, SHIMIZU N, NISHIKAWA T: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
14. ISHII K, AMAGAI M, HALL RP et al.: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-7.
15. KAZATCHKINE MD, KAVERI SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
16. SULTAN Y, KAZATCHKINE MD, MAISSONEUVE P, NYDEGGER UE: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
17. SHOENFELD Y, KATZ U: IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38:123-37.
18. SHERER Y, LEVY Y, FABRIZZI F, SHOENFELD Y: Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 1999; 35: 513-8.
19. BYSTRYN JC, JIAO D, NATOW S: Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358-63.
20. MIMONI D, BLANK M, ASHKENAZI L et al.: Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005; 142: 426-32.
21. REUNALA T: Dermatitis herpetiformis. Clin Dermatol 2001; 19: 728-36.
22. GARIOCH JJ, LEWIS HM, SARGENT SA, LEONARD JN, FRY L: 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131: 541-5.
23. ZONE JJ, MEYER LJ, PETERSEN MJ: Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996; 132: 912-8.
24. DIETERICH W, EHNIS T, BAUER M et al.: Identification of tissue transglutaminase as autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
25. SARDY M, KARPATI S, MERKL B, PAULSSON M, SMYTH N: Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747-7.
26. REIF S, LERNER A: Tissue transglutaminase - the key player in celiac disease: a review. Autoimm Rew 2004; 3: 40-5.
27. MARIETTA E, BLACK K, CAMILLERI M et al.: A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004; 114: 1090-7.
28. SUDA T, SUZUKI Y, MATSUI T et al.: Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br J Dermatol 2005; 152: 887-95.
29. HERVONEN K, HAKANEN M, KAUKINEN K, COLLIN P, REUNALA T: First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis. Scand J Gastroenterol 2002; 37: 51-5.
30. REUNALA T, COLLIN P: Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997; 136: 315-8.
31. HERVONEN K, VORNANEN M, KAUTIAINEN H, COLLIN P, REUNALA T: Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol 2005; 152: 82-6.
32. LEWIS HM, REUNALA TL, GARIOCH JJ et al.: Protective effect of gluten-free diet against lymphoma in dermatitis herpetiformis: Br J Dermatol 1996; 135: 363-7.
33. COLLIN P, PUKKALA E, REUNALA T: Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996: 38: 528-30.
34. DIBBERN DA Jr, DRESKIN SC: Urticaria and angioedema: an overview. Immunol Allergy Clin North Am 2004; 24: 141-62.
35. GROB JJ, REVUZ J, ORTONNE JP, AUQUIER P, LORETTE G: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289-95.
36. ZUBERBIER T: Urticaria. Allergy 2003; 58: 1224-34.
37. WEDI B, RAAP U, KAPP A: Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004; 4: 387-96.
38. DRESKIN SC, ANDREWS KY: The thyroid and urticaria. Curr Opin Allergy Clin Immunol 2005; 5: 408-12.
39. KAPLAN AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465-74.
40. SHEIKH J: Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they ? Curr Opin Allergy Clin Immunol 2005; 5: 403-7.